Clovis Oncology Inc (CLVS)

9.59 +0.73  +8.24% NASDAQ Dec 6, 10:03 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/26/2020 16:30 EST Misc Clovis Oncology Inc Fourth Quarter Earnings Conference Call in 2019
02/26/2020 Earnings Clovis Oncology Inc Fourth Quarter Earnings in 2019 Release
11/07/2019 08:30 EST Misc Clovis Oncology Inc Third Quarter Earnings Conference Call for 2019
11/07/2019 Earnings Clovis Oncology Inc Third Quarter Earnings in 2019 Release
08/01/2019 Earnings Clovis Oncology Inc Second Quarter Earnings in 2019 Release
08/01/2019 08:30 EDT Misc Clovis Oncology Inc Second Quarter Earnings Conference Call in 2019
06/06/2019 08:30 MDT Misc Clovis Oncology Inc Annual General Meeting in 2018
05/07/2019 08:30 EDT Misc Clovis Oncology Inc First Quarter Earnings Conference Call in 2019
05/07/2019 Earnings Clovis Oncology Inc First Quarter Earnings in 2019 Release
02/28/2019 Misc Clovis Oncology Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.clovisoncology.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-IRHome
  • HQ State/Province: Colorado
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Feb. 26, 2020
  • Last Earnings Release: Nov. 07, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Top Fund Holders

Symbol Name Weighting
F0000109F2 FT Biotechnology 40 CA 0.75%
FWLNCX FT Biotechnology 39 RE 0.67%
ISMD Inspire Small/Mid Cap Impact ETF 0.37%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.